178 related articles for article (PubMed ID: 15336652)
1. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.
Benedict WF; Tao Z; Kim CS; Zhang X; Zhou JH; Adam L; McConkey DJ; Papageorgiou A; Munsell M; Philopena J; Engler H; Demers W; Maneval DC; Dinney CP; Connor RJ
Mol Ther; 2004 Sep; 10(3):525-32. PubMed ID: 15336652
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.
Zhang X; Yang Z; Dong L; Papageorgiou A; McConkey DJ; Benedict WF
Cancer Gene Ther; 2007 Mar; 14(3):241-50. PubMed ID: 17096027
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.
Tao Z; Connor RJ; Ashoori F; Dinney CP; Munsell M; Philopena JA; Benedict WF
Cancer Gene Ther; 2006 Feb; 13(2):125-30. PubMed ID: 16082384
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.
Navai N; Benedict WF; Zhang G; Abraham A; Ainslie N; Shah JB; Grossman HB; Kamat AM; Dinney CP
Ann Surg Oncol; 2016 Nov; 23(12):4110-4114. PubMed ID: 27387678
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.
Nagabhushan TL; Maneval DC; Benedict WF; Wen SF; Ihnat PM; Engler H; Connor RJ
Cytokine Growth Factor Rev; 2007; 18(5-6):389-94. PubMed ID: 17692556
[TBL] [Abstract][Full Text] [Related]
7. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
Shore ND; Boorjian SA; Canter DJ; Ogan K; Karsh LI; Downs TM; Gomella LG; Kamat AM; Lotan Y; Svatek RS; Bivalacqua TJ; Grubb RL; Krupski TL; Lerner SP; Woods ME; Inman BA; Milowsky MI; Boyd A; Treasure FP; Gregory G; Sawutz DG; Yla-Herttuala S; Parker NR; Dinney CPN
J Clin Oncol; 2017 Oct; 35(30):3410-3416. PubMed ID: 28834453
[TBL] [Abstract][Full Text] [Related]
8. Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced.
Zhang XQ; Dunner K; Benedict WF
Cancer Gene Ther; 2010 Aug; 17(8):579-84. PubMed ID: 20489789
[TBL] [Abstract][Full Text] [Related]
9. Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity.
Zhang XQ; Yang Z; Benedict WF
Cancer Gene Ther; 2011 Apr; 18(4):260-4. PubMed ID: 21183949
[TBL] [Abstract][Full Text] [Related]
10. Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.
Yang Z; Zhang XQ; Dinney CN; Benedict WF
Cancer Gene Ther; 2011 Sep; 18(9):609-16. PubMed ID: 21681220
[TBL] [Abstract][Full Text] [Related]
11. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Fisher MB; Zhang XQ; McConkey DJ; Benedict WF
Cancer Gene Ther; 2009 Jul; 16(7):567-72. PubMed ID: 19197325
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
[TBL] [Abstract][Full Text] [Related]
13. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
14. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.
Yamashita M; Rosser CJ; Zhou JH; Zhang XQ; Connor RJ; Engler H; Maneval DC; Karashima T; Czerniak BA; Dinney CP; Benedict WF
Cancer Gene Ther; 2002 Aug; 9(8):687-91. PubMed ID: 12136430
[TBL] [Abstract][Full Text] [Related]
15. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.
Connor RJ; Anderson JM; Machemer T; Maneval DC; Engler H
Urology; 2005 Jul; 66(1):224-9. PubMed ID: 15992886
[TBL] [Abstract][Full Text] [Related]
16. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
18. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect.
Zhang X; Dong L; Chapman E; Benedict WF
Cancer Gene Ther; 2008 Dec; 15(12):817-22. PubMed ID: 18617914
[TBL] [Abstract][Full Text] [Related]
19. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
20. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
Kuball J; Wen SF; Leissner J; Atkins D; Meinhardt P; Quijano E; Engler H; Hutchins B; Maneval DC; Grace MJ; Fritz MA; Störkel S; Thüroff JW; Huber C; Schuler M
J Clin Oncol; 2002 Feb; 20(4):957-65. PubMed ID: 11844817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
